The clinical trial: “A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia (ACH)” will have a new cohort of up to 60mg/kg. This information was obtain in the clinicaltrial.gov page.

Cohort 4 has recently begun with a 30mg/kg/subcutaneous injection daily. And now, a cohort 5 is planned too.

Cohort: is any group of people who are linked in some way and followed over time.

BMN-111 Phase 2

Estimated Primary Completion Date:December 2018 (Final data collection date for primary outcome measure)

Estimated Study Completion Date: January 2019

Experimental: BMN 111 – Subcutaneous Injection, open-label sequential cohort dose-escalation study. BMN 111 will be administered as a morning dose in one of the following daily dosing regimens:

Phase 3 will probably start in the first trimester of 2016. The inclusion and exclusion criteria for phase 3 have not been revealed yet.